GENTAUR Belgium BVBA BE0473327336 Voortstraat 49, 1910 Kampenhout BELGIUM Tel 0032 16 58 90 45
GENTAUR U.S.A Genprice Inc,Logistics 547 Yurok Circle, SanJose, CA 95123
Tel (408) 780-0908, Fax (408) 780-0908, [email protected]

Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, Gentaur another in time delivery

Interleukin-4 receptor subunit alpha (IL-4 receptor subunit alpha) (IL-4R subunit alpha) (IL-4R-alpha) (IL-4RA) (CD antigen CD124) [Cleaved into: Soluble interleukin-4 receptor subunit alpha (Soluble IL-4 receptor subunit alpha) (Soluble IL-4R-alpha) (sIL4Ralpha/prot) (IL-4-binding protein) (IL4-BP)]

 IL4RA_HUMAN             Reviewed;         825 AA.
P24394; B4E076; B9EKU8; H3BSY5; Q96P01; Q9H181; Q9H182; Q9H183; Q9H184;
Q9H185; Q9H186; Q9H187; Q9H188;
01-MAR-1992, integrated into UniProtKB/Swiss-Prot.
01-MAR-1992, sequence version 1.
12-AUG-2020, entry version 223.
RecName: Full=Interleukin-4 receptor subunit alpha;
Short=IL-4 receptor subunit alpha;
Short=IL-4R subunit alpha;
Short=IL-4R-alpha;
Short=IL-4RA;
AltName: CD_antigen=CD124;
Contains:
RecName: Full=Soluble interleukin-4 receptor subunit alpha;
Short=Soluble IL-4 receptor subunit alpha;
Short=Soluble IL-4R-alpha;
Short=sIL4Ralpha/prot;
AltName: Full=IL-4-binding protein;
Short=IL4-BP;
Flags: Precursor;
Name=IL4R; Synonyms=IL4RA; ORFNames=582J2.1;
Homo sapiens (Human).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
Homo.
NCBI_TaxID=9606;
[1]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
TISSUE=Peripheral blood;
PubMed=2307934; DOI=10.1084/jem.171.3.861;
Idzerda R.L., March C.J., Mosley B., Lyman S.D., Bos T.V., Gimpel S.D.,
Din W.S., Grabstein K.H., Widmer M.B., Park L.S., Cosman D., Beckmann M.P.;
"Human interleukin 4 receptor confers biological responsiveness and defines
a novel receptor superfamily.";
J. Exp. Med. 171:861-873(1990).
[2]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
TISSUE=Myeloid leukemia cell;
PubMed=2278997; DOI=10.1093/intimm/2.7.669;
Galizzi J.-P., Zuber C.E., Harada N., Gorman D.M., Djossou O.,
Kastelein R., Banchereau J., Howard M., Miyajima A.;
"Molecular cloning of a cDNA encoding the human interleukin 4 receptor.";
Int. Immunol. 2:669-675(1990).
[3]
NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING.
TISSUE=Blood;
PubMed=10590262; DOI=10.1093/intimm/11.12.1965;
Kruse S., Forster J., Kuehr J., Deichmann K.A.;
"Characterization of the membrane-bound and a soluble form of human IL-4
receptor alpha produced by alternative splicing.";
Int. Immunol. 11:1965-1970(1999).
[4]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ISOFORM 1).
PubMed=10493829; DOI=10.1006/geno.1999.5927;
Loftus B.J., Kim U.-J., Sneddon V.P., Kalush F., Brandon R., Fuhrmann J.,
Mason T., Crosby M.L., Barnstead M., Cronin L., Mays A.D., Cao Y., Xu R.X.,
Kang H.-L., Mitchell S., Eichler E.E., Harris P.C., Venter J.C.,
Adams M.D.;
"Genome duplications and other features in 12 Mb of DNA sequence from human
chromosome 16p and 16q.";
Genomics 60:295-308(1999).
[5]
NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-75; ALA-400; ARG-431;
LEU-436; PRO-503; ARG-576; ILE-579; SER-675 AND ALA-752.
SeattleSNPs variation discovery resource;
Submitted (SEP-2001) to the EMBL/GenBank/DDBJ databases.
[6]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
TISSUE=Thymus;
PubMed=14702039; DOI=10.1038/ng1285;
Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
Isogai T., Sugano S.;
"Complete sequencing and characterization of 21,243 full-length human
cDNAs.";
Nat. Genet. 36:40-45(2004).
[7]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
PubMed=15616553; DOI=10.1038/nature03187;
Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G.,
Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E.,
Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M.,
Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C.,
Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M.,
Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M.,
Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D.,
Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L.,
Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E.,
Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H.,
Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y.,
Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S.,
Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A.,
Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M.,
Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H.,
Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A.,
Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J.,
DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J.,
Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M.,
Myers R.M., Rubin E.M., Pennacchio L.A.;
"The sequence and analysis of duplication-rich human chromosome 16.";
Nature 432:988-994(2004).
[8]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
TISSUE=Testis;
PubMed=15489334; DOI=10.1101/gr.2596504;
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA project:
the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
[9]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 301-825 (ISOFORM 1), AND VARIANTS
ALA-400; ARG-431; LEU-436; PRO-503; ARG-576 AND ILE-579.
PubMed=11285129; DOI=10.1034/j.1399-0039.2001.057003216.x;
Lozano F., Places L., Vila J.-M., Padilla O., Arman M., Gimferrer I.,
Suarez B., Lopez de la Iglesia A., Miserachs N., Vives J.;
"Identification of a novel single-nucleotide polymorphism (Val554Ile) and
definition of eight common alleles for human IL4RA exon 11.";
Tissue Antigens 57:216-220(2001).
[10]
FUNCTION IN IRS1 ACTIVATION, PHOSPHORYLATION AT TYR-497, AND MUTAGENESIS OF
TYR-497.
PubMed=8124718; DOI=10.1016/0092-8674(94)90356-5;
Keegan A.D., Nelms K., White M., Wang L.-M., Pierce J.H., Paul W.E.;
"An IL-4 receptor region containing an insulin receptor motif is important
for IL-4-mediated IRS-1 phosphorylation and cell growth.";
Cell 76:811-820(1994).
[11]
DOMAIN JAK3 ACTIVATION.
PubMed=7721895; DOI=10.1074/jbc.270.16.9630;
Malabarba M.G., Kirken R.A., Rui H., Koettnitz K., Kawamura M.,
O'Shea J.J., Kalthoff F.S., Farrar W.L.;
"Activation of JAK3, but not JAK1, is critical to interleukin-4 (IL4)
stimulated proliferation and requires a membrane-proximal region of IL4
receptor alpha.";
J. Biol. Chem. 270:9630-9637(1995).
[12]
INTERACTION WITH IL13RA1.
PubMed=7775445; DOI=10.1074/jbc.270.23.13869;
Zurawski S.M., Chomarat P., Djossou O., Bidaud C., McKenzie A.N.,
Miossec P., Banchereau J., Zurawski G.;
"The primary binding subunit of the human interleukin-4 receptor is also a
component of the interleukin-13 receptor.";
J. Biol. Chem. 270:13869-13878(1995).
[13]
INTERACTION WITH JAK3.
PubMed=7538655;
Rolling C., Treton D., Beckmann P., Galanaud P., Richard Y.;
"JAK3 associates with the human interleukin 4 receptor and is tyrosine
phosphorylated following receptor triggering.";
Oncogene 10:1757-1761(1995).
[14]
INTERACTION WITH IL13RA1, AND PHOSPHORYLATION.
PubMed=8804422; DOI=10.1016/0014-5793(96)00835-6;
Rolling C., Treton D., Pellegrini S., Galanaud P., Richard Y.;
"IL4 and IL13 receptors share the gamma c chain and activate STAT6, STAT3
and STAT5 proteins in normal human B cells.";
FEBS Lett. 393:53-56(1996).
[15]
DOMAIN STAT6 ACTIVATION, MUTAGENESIS OF TYR-575; TYR-603 AND TYR-631, AND
PHOSPHORYLATION AT TYR-575; TYR-603 AND TYR-631.
PubMed=8624803; DOI=10.1016/s1074-7613(00)80677-9;
Ryan J.J., McReynolds L.J., Keegan A., Wang L.-H., Garfein E., Rothman P.,
Nelms K., Paul W.E.;
"Growth and gene expression are predominantly controlled by distinct
regions of the human IL-4 receptor.";
Immunity 4:123-132(1996).
[16]
PROTEOLYTIC PROCESSING.
PubMed=10341317; DOI=10.1159/000024171;
Jung T., Schrader N., Hellwig M., Enssle K.H., Neumann C.;
"Soluble human interleukin-4 receptor is produced by activated T cells
under the control of metalloproteinases.";
Int. Arch. Allergy Immunol. 119:23-30(1999).
[17]
INTERACTION WITH PTPN6; PTPN11 AND INPP5D, STAT6 ACTIVATION, AND
MUTAGENESIS OF TYR-713.
PubMed=11714803; DOI=10.4049/jimmunol.167.11.6382;
Kashiwada M., Giallourakis C.C., Pan P.-Y., Rothman P.B.;
"Immunoreceptor tyrosine-based inhibitory motif of the IL-4 receptor
associates with SH2-containing phosphatases and regulates IL-4-induced
proliferation.";
J. Immunol. 167:6382-6387(2001).
[18]
LIGAND-BINDING SITES, AND MUTAGENESIS OF TYR-38; MET-39; SER-40; LEU-64;
PHE-66; LEU-67; LEU-68; ASP-91; ASP-92; VAL-93; VAL-94; SER-95; ASP-97;
ASN-98; TYR-99; LYS-116; PRO-117; SER-118; GLU-119; ASP-150; ASN-151;
TYR-152; LEU-153; TYR-154 AND TYR-208.
PubMed=11786020; DOI=10.1006/jmbi.2001.5243;
Zhang J.-L., Simeonowa I., Wang Y., Sebald W.;
"The high-affinity interaction of human IL-4 and the receptor alpha chain
is constituted by two independent binding clusters.";
J. Mol. Biol. 315:399-407(2002).
[19]
STAT6 ACTIVATION, AND INHIBITION BY TYROSINE PHOSPHATASE SHP1.
PubMed=12459556; DOI=10.1074/jbc.m211747200;
Hanson E.M., Dickensheets H., Qu C.K., Donnelly R.P., Keegan A.D.;
"Regulation of the dephosphorylation of Stat6. Participation of Tyr-713 in
the interleukin-4 receptor alpha, the tyrosine phosphatase SHP-1, and the
proteasome.";
J. Biol. Chem. 278:3903-3911(2003).
[20]
X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 26-232 IN COMPLEX WITH IL4.
PubMed=10219247; DOI=10.1016/s0092-8674(00)80736-9;
Hage T., Sebald W., Reinemer P.;
"Crystal structure of the interleukin-4/receptor alpha chain complex
reveals a mosaic binding interface.";
Cell 97:271-281(1999).
[21]
VARIANTS VAL-75; ALA-400; ARG-431; LEU-436 AND PRO-786.
PubMed=9070874; DOI=10.1006/bbrc.1997.6115;
Deichmann K., Bardutzky J., Forster J., Heinzmann A., Kuehr J.;
"Common polymorphisms in the coding part of the IL4-receptor gene.";
Biochem. Biophys. Res. Commun. 231:696-697(1997).
[22]
VARIANT ARG-576.
PubMed=9392697; DOI=10.1056/nejm199712113372403;
Hershey G.K.K., Friedrich M.F., Esswein L.A., Thomas M.L., Chatila T.A.;
"The association of atopy with a gain-of-function mutation in the alpha
subunit of the interleukin-4 receptor.";
N. Engl. J. Med. 337:1720-1725(1997).
[23]
VARIANT VAL-75.
PubMed=9620765; DOI=10.1038/472;
Mitsuyasu H., Izuhara K., Mao X.-Q., Gao P.S., Arinobu Y., Enomoto T.,
Kawai M., Sasaki S., Dake Y., Hamasaki N., Shirakawa T., Hopkin J.M.;
"Ile50Val variant of IL4R alpha upregulates IgE synthesis and associates
with atopic asthma.";
Nat. Genet. 19:119-120(1998).
[24]
VARIANT VAL-75.
PubMed=10390422; DOI=10.1164/ajrccm.160.1.9807130;
Noguchi E., Shibasaki M., Arinami T., Takeda K., Yokouchi Y., Kobayashi K.,
Imoto N., Nakahara S., Matsui A., Hamaguchi H.;
"No association between atopy/asthma and the Ile50Val polymorphism of IL-4
receptor.";
Am. J. Respir. Crit. Care Med. 160:342-345(1999).
[25]
VARIANTS PRO-503 AND ARG-576.
PubMed=10233717; DOI=10.1046/j.1365-2567.1999.00705.x;
Kruse S., Japha T., Tedner M., Sparholt S.H., Forster J., Kuehr J.,
Deichmann K.A.;
"The polymorphisms S503P and Q576R in the interleukin-4 receptor alpha gene
are associated with atopy and influence the signal transduction.";
Immunology 96:365-371(1999).
[26]
CHARACTERIZATION OF VARIANT ARG-576, AND MUTAGENESIS OF TYR-575.
PubMed=10201973;
Wang H.Y., Shelburne C.P., Zamorano J., Kelly A.E., Ryan J.J., Keegan A.D.;
"Effects of an allergy-associated mutation in the human IL-4R alpha (Q576R)
on human IL-4-induced signal transduction.";
J. Immunol. 162:4385-4389(1999).
[27]
VARIANT ALA-752.
PubMed=10677312; DOI=10.1086/302781;
Ober C., Leavitt S.A., Tsalenko A., Howard T.D., Hoki D.M., Daniel R.,
Newman D.L., Wu X., Parry R., Lester L.A., Solway J., Blumenthal M.,
King R.A., Xu J., Meyers D.A., Bleecker E.R., Cox N.J.;
"Variation in the interleukin 4-receptor alpha gene confers susceptibility
to asthma and atopy in ethnically diverse populations.";
Am. J. Hum. Genet. 66:517-526(2000).
[28]
VARIANT ARG-576.
PubMed=10809862; DOI=10.1046/j.1365-2133.2000.03485.x;
Oiso N., Fukai K., Ishii M.;
"Interleukin 4 receptor alpha chain polymorphism Gln551Arg is associated
with adult atopic dermatitis in Japan.";
Br. J. Dermatol. 142:1003-1006(2000).
[29]
VARIANT PRO-786.
PubMed=11513543; DOI=10.1006/clim.2001.5082;
Andrews R.P., Burrell L., Rosa-Rosa L., Cunningham C.M., Brzezinski J.L.,
Bernstein J.A., Khurana Hershey G.K.;
"Analysis of the Ser786Pro interleukin-4 receptor alpha allelic variant in
allergic and nonallergic asthma and its functional consequences.";
Clin. Immunol. 100:298-304(2001).
[30]
VARIANTS VAL-75 AND ALA-400, AND POLYMORPHISM.
PubMed=14657871; DOI=10.1016/j.jaci.2003.08.051;
Nakamura H., Miyagawa K., Ogino K., Endo T., Imai T., Ozasa K.,
Motohashi Y., Matsuzaki I., Sasahara S., Hatta K., Eboshida A.;
"High contribution contrast between the genes of eosinophil peroxidase and
IL-4 receptor alpha-chain in Japanese cedar pollinosis.";
J. Allergy Clin. Immunol. 112:1127-1131(2003).
-!- FUNCTION: Receptor for both interleukin 4 and interleukin 13. Couples
to the JAK1/2/3-STAT6 pathway. The IL4 response is involved in
promoting Th2 differentiation. The IL4/IL13 responses are involved in
regulating IgE production and, chemokine and mucus production at sites
of allergic inflammation. In certain cell types, can signal through
activation of insulin receptor substrates, IRS1/IRS2.
{ECO:0000269|PubMed:8124718}.
-!- FUNCTION: Soluble IL4R (sIL4R) inhibits IL4-mediated cell proliferation
and IL5 up-regulation by T-cells. {ECO:0000269|PubMed:8124718}.
-!- SUBUNIT: The functional IL4 receptor is formed by initial binding of
IL4 to IL4R. Subsequent recruitment to the complex of the common gamma
chain, in immune cells, creates a type I receptor and, in non-immune
cells, of IL13RA1 forms a type II receptor. IL4R can also interact with
the IL13/IL13RA1 complex to form a similar type II receptor
(PubMed:7775445, PubMed:8804422). Interacts with PIK3C3 (By
similarity). Interacts with the SH2-containing phosphatases,
PTPN6/SHIP1, PTPN11/SHIP2 and INPP5D/SHIP (PubMed:11714803). Interacts
with JAK1 through a Box 1-containing region; inhibited by SOCS5.
Interacts with SOCS5; inhibits IL4 signaling (By similarity). Interacts
with JAK3 (PubMed:7538655). Interacts with CLM1 (By similarity).
{ECO:0000250|UniProtKB:P16382, ECO:0000269|PubMed:11714803,
ECO:0000269|PubMed:7538655, ECO:0000269|PubMed:7775445,
ECO:0000269|PubMed:8804422}.
-!- INTERACTION:
P24394; P05112: IL4; NbExp=7; IntAct=EBI-367009, EBI-367025;
P24394; P42226: STAT6; NbExp=4; IntAct=EBI-367009, EBI-1186478;
-!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
protein.
-!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted.
-!- ALTERNATIVE PRODUCTS:
Event=Alternative splicing; Named isoforms=3;
Name=1; Synonyms=Membrane-bound form;
IsoId=P24394-1; Sequence=Displayed;
Name=2; Synonyms=Soluble form, sIL4Ralpha/splice;
IsoId=P24394-2; Sequence=VSP_011116, VSP_011117;
Name=3;
IsoId=P24394-3; Sequence=VSP_053738;
-!- TISSUE SPECIFICITY: Isoform 1 and isoform 2 are highly expressed in
activated T-cells.
-!- DOMAIN: The extracellular domain represents the IL4 binding protein
(IL4BP).
-!- DOMAIN: The WSXWS motif appears to be necessary for proper protein
folding and thereby efficient intracellular transport and cell-surface
receptor binding.
-!- DOMAIN: The box 1 motif is required for JAK interaction and/or
activation.
-!- DOMAIN: Contains 1 copy of a cytoplasmic motif that is referred to as
the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is
involved in modulation of cellular responses. The phosphorylated ITIM
motif can bind the SH2 domain of several SH2-containing phosphatases.
-!- PTM: On IL4 binding, phosphorylated on C-terminal tyrosine residues.
Phosphorylation on any one of tyrosine residues, Tyr-575, Tyr-603 or
Tyr-631, is required for STAT6-induced gene induction.
{ECO:0000269|PubMed:8624803}.
-!- PTM: The soluble form (sIL4R/IL4BP) can also be produced by proteolytic
cleavage at the cell surface (shedding) by a metalloproteinase.
{ECO:0000269|PubMed:10341317}.
-!- POLYMORPHISM: Allelic variants in IL4RA are associated with a
susceptibility to atopy, an immunological condition that can lead to
clinical symptoms such as allergic rhinitis, sinusitis, asthma and
eczema.
-!- POLYMORPHISM: Allelic variants in IL4RA are associated with cedar
pollen sensitization. Individuals develop Japanese cedar pollinosis
with increased exposure to cedar pollen. Japanese cedar pollinosis is a
type I allergic disease with ocular and nasal symptoms that develop
paroxysmally on contact with Japanese cedar pollen. These symptoms,
which occur seasonally each year, are typical features of allergic
rhinitis, such as sneezing, excessive nasal secretion, nasal
congestion, and conjunctival itching.
-!- SIMILARITY: Belongs to the type I cytokine receptor family. Type 4
subfamily. {ECO:0000305}.
-!- WEB RESOURCE: Name=SeattleSNPs;
URL="http://pga.gs.washington.edu/data/il4r/";
-!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
polymorphism database;
URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=IL4R";
---------------------------------------------------------------------------
Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
Distributed under the Creative Commons Attribution (CC BY 4.0) License
---------------------------------------------------------------------------
EMBL; X52425; CAA36672.1; -; mRNA.
EMBL; AC004525; AAC23495.1; -; Genomic_DNA.
EMBL; AF421855; AAL12163.1; -; Genomic_DNA.
EMBL; AJ293647; CAC20445.1; -; Genomic_DNA.
EMBL; AJ293648; CAC20446.1; -; Genomic_DNA.
EMBL; AJ293649; CAC20447.1; -; Genomic_DNA.
EMBL; AJ293650; CAC20448.1; -; Genomic_DNA.
EMBL; AJ293651; CAC20449.1; -; Genomic_DNA.
EMBL; AJ293652; CAC20450.1; -; Genomic_DNA.
EMBL; AJ293653; CAC20451.1; -; Genomic_DNA.
EMBL; AK303255; BAG64338.1; -; mRNA.
EMBL; AC106739; -; NOT_ANNOTATED_CDS; Genomic_DNA.
EMBL; BC151131; AAI51132.1; -; mRNA.
EMBL; AJ293654; CAC20452.1; -; Genomic_DNA.
CCDS; CCDS10629.1; -. [P24394-1]
CCDS; CCDS58441.1; -. [P24394-3]
PIR; A60386; A60386.
RefSeq; NP_000409.1; NM_000418.3. [P24394-1]
RefSeq; NP_001244335.1; NM_001257406.1. [P24394-1]
RefSeq; NP_001244336.1; NM_001257407.1. [P24394-3]
RefSeq; XP_011544127.1; XM_011545825.1. [P24394-1]
RefSeq; XP_011544128.1; XM_011545826.2. [P24394-1]
RefSeq; XP_011544129.1; XM_011545827.2. [P24394-1]
PDB; 1IAR; X-ray; 2.30 A; B=26-232.
PDB; 1IRS; NMR; -; B=489-499.
PDB; 1ITE; Model; -; C=26-232.
PDB; 3BPL; X-ray; 2.93 A; B=27-227.
PDB; 3BPN; X-ray; 3.02 A; B=27-227.
PDB; 3BPO; X-ray; 3.00 A; B=27-227.
PDB; 5E4E; X-ray; 3.00 A; B=26-228.
PDB; 6OEL; X-ray; 3.10 A; B=27-224.
PDBsum; 1IAR; -.
PDBsum; 1IRS; -.
PDBsum; 1ITE; -.
PDBsum; 3BPL; -.
PDBsum; 3BPN; -.
PDBsum; 3BPO; -.
PDBsum; 5E4E; -.
PDBsum; 6OEL; -.
SMR; P24394; -.
BioGRID; 109780; 41.
CORUM; P24394; -.
DIP; DIP-3223N; -.
ELM; P24394; -.
IntAct; P24394; 34.
MINT; P24394; -.
STRING; 9606.ENSP00000379111; -.
ChEMBL; CHEMBL3580490; -.
DrugBank; DB05078; AER001.
DrugBank; DB12159; Dupilumab.
DrugCentral; P24394; -.
GuidetoPHARMACOLOGY; 1697; -.
TCDB; 9.B.281.1.9; the interleukin-2 receptor (il2r) family.
GlyConnect; 2053; 1 N-Linked glycan (1 site).
GlyGen; P24394; 6 sites, 1 N-linked glycan (1 site).
iPTMnet; P24394; -.
PhosphoSitePlus; P24394; -.
BioMuta; IL4R; -.
DMDM; 124335; -.
jPOST; P24394; -.
MassIVE; P24394; -.
PaxDb; P24394; -.
PeptideAtlas; P24394; -.
PRIDE; P24394; -.
ProteomicsDB; 54203; -. [P24394-1]
ProteomicsDB; 54204; -. [P24394-2]
ProteomicsDB; 5656; -.
ABCD; P24394; 3 sequenced antibodies.
Antibodypedia; 3843; 623 antibodies.
Ensembl; ENST00000170630; ENSP00000170630; ENSG00000077238. [P24394-3]
Ensembl; ENST00000395762; ENSP00000379111; ENSG00000077238. [P24394-1]
Ensembl; ENST00000543915; ENSP00000441667; ENSG00000077238. [P24394-1]
GeneID; 3566; -.
KEGG; hsa:3566; -.
UCSC; uc002don.5; human. [P24394-1]
CTD; 3566; -.
DisGeNET; 3566; -.
EuPathDB; HostDB:ENSG00000077238.13; -.
GeneCards; IL4R; -.
HGNC; HGNC:6015; IL4R.
HPA; ENSG00000077238; Low tissue specificity.
MalaCards; IL4R; -.
MIM; 147781; gene.
neXtProt; NX_P24394; -.
OpenTargets; ENSG00000077238; -.
PharmGKB; PA29832; -.
eggNOG; ENOG502S3Y8; Eukaryota.
GeneTree; ENSGT00510000049182; -.
HOGENOM; CLU_020561_0_0_1; -.
InParanoid; P24394; -.
KO; K05071; -.
OMA; WCPVEVS; -.
PhylomeDB; P24394; -.
TreeFam; TF337996; -.
PathwayCommons; P24394; -.
Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
SignaLink; P24394; -.
SIGNOR; P24394; -.
BioGRID-ORCS; 3566; 3 hits in 873 CRISPR screens.
ChiTaRS; IL4R; human.
EvolutionaryTrace; P24394; -.
GeneWiki; Interleukin-4_receptor; -.
GenomeRNAi; 3566; -.
Pharos; P24394; Tclin.
PRO; PR:P24394; -.
Proteomes; UP000005640; Chromosome 16.
RNAct; P24394; protein.
Bgee; ENSG00000077238; Expressed in left adrenal gland and 206 other tissues.
ExpressionAtlas; P24394; baseline and differential.
Genevisible; P24394; HS.
GO; GO:0034451; C:centriolar satellite; IDA:HPA.
GO; GO:0005615; C:extracellular space; IEA:Ensembl.
GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
GO; GO:0005654; C:nucleoplasm; IDA:HPA.
GO; GO:0005886; C:plasma membrane; IDA:HPA.
GO; GO:0043235; C:receptor complex; IDA:MGI.
GO; GO:0004913; F:interleukin-4 receptor activity; TAS:ProtInc.
GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
GO; GO:0042832; P:defense response to protozoan; IEA:Ensembl.
GO; GO:0006955; P:immune response; TAS:ProtInc.
GO; GO:0016064; P:immunoglobulin mediated immune response; IEA:Ensembl.
GO; GO:0045626; P:negative regulation of T-helper 1 cell differentiation; IEA:Ensembl.
GO; GO:0030728; P:ovulation; IEA:Ensembl.
GO; GO:0090197; P:positive regulation of chemokine secretion; IEA:Ensembl.
GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; ISS:YuBioLab.
GO; GO:0002639; P:positive regulation of immunoglobulin production; IEA:Ensembl.
GO; GO:0043032; P:positive regulation of macrophage activation; IEA:Ensembl.
GO; GO:0043306; P:positive regulation of mast cell degranulation; IEA:Ensembl.
GO; GO:1901741; P:positive regulation of myoblast fusion; IEA:Ensembl.
GO; GO:0045630; P:positive regulation of T-helper 2 cell differentiation; IEA:Ensembl.
GO; GO:0002532; P:production of molecular mediator involved in inflammatory response; IEA:InterPro.
GO; GO:0042127; P:regulation of cell population proliferation; IEA:Ensembl.
GO; GO:0043627; P:response to estrogen; IEA:Ensembl.
GO; GO:1990834; P:response to odorant; IEA:Ensembl.
GO; GO:0007165; P:signal transduction; TAS:ProtInc.
CDD; cd00063; FN3; 1.
Gene3D; 2.60.40.10; -; 2.
IDEAL; IID00653; -.
InterPro; IPR003961; FN3_dom.
InterPro; IPR036116; FN3_sf.
InterPro; IPR003531; Hempt_rcpt_S_F1_CS.
InterPro; IPR013783; Ig-like_fold.
InterPro; IPR015319; IL-4_rcpt-alpha_N.
Pfam; PF09238; IL4Ra_N; 1.
SUPFAM; SSF49265; SSF49265; 2.
PROSITE; PS50853; FN3; 1.
PROSITE; PS01355; HEMATOPO_REC_S_F1; 1.
1: Evidence at protein level;
3D-structure; Alternative splicing; Cell membrane; Disulfide bond;
Glycoprotein; Immunity; Membrane; Phosphoprotein; Polymorphism; Receptor;
Reference proteome; Secreted; Signal; Transmembrane; Transmembrane helix.
SIGNAL 1..25
/evidence="ECO:0000250"
CHAIN 26..825
/note="Interleukin-4 receptor subunit alpha"
/id="PRO_0000010887"
CHAIN 26..?
/note="Soluble interleukin-4 receptor subunit alpha"
/id="PRO_0000010888"
TOPO_DOM 26..232
/note="Extracellular"
/evidence="ECO:0000255"
TRANSMEM 233..256
/note="Helical"
/evidence="ECO:0000255"
TOPO_DOM 257..825
/note="Cytoplasmic"
/evidence="ECO:0000255"
DOMAIN 125..224
/note="Fibronectin type-III"
/evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
REGION 437..557
/note="Required for IRS1 activation and IL4-induced cell
growth"
REGION 558..657
/note="Required for IL4-induced gene expression"
MOTIF 212..216
/note="WSXWS motif"
MOTIF 262..270
/note="Box 1 motif"
MOTIF 711..716
/note="ITIM motif"
COMPBIAS 370..380
/note="Poly-Glu"
COMPBIAS 563..566
/note="Poly-Ala"
COMPBIAS 789..794
/note="Poly-Ser"
SITE 38
/note="Major IL4 binding determinant"
SITE 64
/note="Minor IL4 binding determinant"
SITE 66
/note="Minor IL4 binding determinant"
SITE 92
/note="Minor IL4 binding determinant"
SITE 94
/note="Minor IL4 binding determinant"
SITE 97
/note="Major IL4 binding determinant"
SITE 152
/note="Minor IL4 binding determinant"
SITE 208
/note="Major IL4 binding determinant"
MOD_RES 497
/note="Phosphotyrosine"
/evidence="ECO:0000269|PubMed:8124718"
MOD_RES 575
/note="Phosphotyrosine"
/evidence="ECO:0000305|PubMed:8624803"
MOD_RES 603
/note="Phosphotyrosine"
/evidence="ECO:0000305|PubMed:8624803"
MOD_RES 631
/note="Phosphotyrosine"
/evidence="ECO:0000305|PubMed:8624803"
CARBOHYD 53
/note="N-linked (GlcNAc...) asparagine"
/evidence="ECO:0000255"
CARBOHYD 98
/note="N-linked (GlcNAc...) asparagine"
/evidence="ECO:0000255"
CARBOHYD 128
/note="N-linked (GlcNAc...) asparagine"
/evidence="ECO:0000255"
CARBOHYD 134
/note="N-linked (GlcNAc...) asparagine"
/evidence="ECO:0000255"
CARBOHYD 176
/note="N-linked (GlcNAc...) asparagine"
/evidence="ECO:0000255"
CARBOHYD 209
/note="N-linked (GlcNAc...) asparagine"
/evidence="ECO:0000255"
DISULFID 34..44
/evidence="ECO:0000250"
DISULFID 74..86
/evidence="ECO:0000250"
VAR_SEQ 1..23
/note="MGWLCSGLLFPVSCLVLLQVASS -> MQKDARRE (in isoform 3)"
/evidence="ECO:0000303|PubMed:14702039"
/id="VSP_053738"
VAR_SEQ 225..227
/note="YRE -> NIC (in isoform 2)"
/evidence="ECO:0000305"
/id="VSP_011116"
VAR_SEQ 228..825
/note="Missing (in isoform 2)"
/evidence="ECO:0000305"
/id="VSP_011117"
VARIANT 75
/note="I -> F (in dbSNP:rs1805010)"
/id="VAR_059302"
VARIANT 75
/note="I -> L (in dbSNP:rs1805010)"
/id="VAR_059303"
VARIANT 75
/note="I -> V (associated with atopic asthma and cedar
pollen sensitization; dbSNP:rs1805010)"
/evidence="ECO:0000269|PubMed:10390422,
ECO:0000269|PubMed:14657871, ECO:0000269|PubMed:9070874,
ECO:0000269|PubMed:9620765, ECO:0000269|Ref.5"
/id="VAR_008034"
VARIANT 387
/note="S -> L (in dbSNP:rs6413500)"
/id="VAR_019999"
VARIANT 400
/note="E -> A (associated with cedar pollen sensitization;
dbSNP:rs1805011)"
/evidence="ECO:0000269|PubMed:11285129,
ECO:0000269|PubMed:14657871, ECO:0000269|PubMed:9070874,
ECO:0000269|Ref.5"
/id="VAR_011657"
VARIANT 431
/note="C -> R (in dbSNP:rs1805012)"
/evidence="ECO:0000269|PubMed:11285129,
ECO:0000269|PubMed:9070874, ECO:0000269|Ref.5"
/id="VAR_011658"
VARIANT 436
/note="S -> L (in dbSNP:rs1805013)"
/evidence="ECO:0000269|PubMed:11285129,
ECO:0000269|PubMed:9070874, ECO:0000269|Ref.5"
/id="VAR_011659"
VARIANT 492
/note="A -> T (in dbSNP:rs35606110)"
/id="VAR_049164"
VARIANT 492
/note="A -> V (in dbSNP:rs34727572)"
/id="VAR_049165"
VARIANT 503
/note="S -> P (lowered total IgE concentration;
dbSNP:rs1805015)"
/evidence="ECO:0000269|PubMed:10233717,
ECO:0000269|PubMed:11285129, ECO:0000269|Ref.5"
/id="VAR_011660"
VARIANT 576
/note="Q -> R (associated with atopic dermatitis; lowered
total IgE concentration; no effect on IL4-induced signal
transduction; dbSNP:rs1801275)"
/evidence="ECO:0000269|PubMed:10201973,
ECO:0000269|PubMed:10233717, ECO:0000269|PubMed:10809862,
ECO:0000269|PubMed:11285129, ECO:0000269|PubMed:9392697,
ECO:0000269|Ref.5"
/id="VAR_008035"
VARIANT 579
/note="V -> I (in dbSNP:rs3024677)"
/evidence="ECO:0000269|PubMed:11285129, ECO:0000269|Ref.5"
/id="VAR_011661"
VARIANT 675
/note="P -> S (in dbSNP:rs3024678)"
/evidence="ECO:0000269|Ref.5"
/id="VAR_020000"
VARIANT 752
/note="S -> A (in dbSNP:rs1805016)"
/evidence="ECO:0000269|PubMed:10677312, ECO:0000269|Ref.5"
/id="VAR_011662"
VARIANT 786
/note="S -> P (in 1.8% of the population; dbSNP:rs1805014)"
/evidence="ECO:0000269|PubMed:11513543,
ECO:0000269|PubMed:9070874"
/id="VAR_011663"
MUTAGEN 38
/note="Y->A: 700-fold reduction in IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 38
/note="Y->F: 25-fold reduction in IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 39
/note="M->A: No effect on IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 40
/note="S->A: No effect on IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 64
/note="L->A: 100-fold reduction in IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 66
/note="F->A: 45-fold reduction in IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 67
/note="L->A: No effect on IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 68
/note="L->A: No effect on IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 91
/note="D->A: Little effect on IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 92
/note="D->A: 50-fold reduction in IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 93
/note="V->A: Little effect on IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 94
/note="V->A: 35-fold reduction in IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 95
/note="S->A: No effect on IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 97
/note="D->A,N: >150-fold reduction in IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 98
/note="N->A: No effect on IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 99
/note="Y->A: 10-fold reduction in IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 116
/note="K->A: Little effect on IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 117
/note="P->A: Little effect on IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 118
/note="S->A: No effect on IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 119
/note="E->A: No effect on IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 150
/note="D->A: Little effect on IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 151
/note="N->A: Little effect on IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 152
/note="Y->A: 40-fold reduction in IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 152
/note="Y->F: No effect on IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 153
/note="L->A: Little effect on IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 154
/note="Y->A: Little effect on IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 208
/note="Y->A: 500-fold reduction in IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 208
/note="Y->F: 200-fold reduction in IL4 binding."
/evidence="ECO:0000269|PubMed:11786020"
MUTAGEN 497
/note="Y->F: Abolishes IRS1 tyrosine phosphorylation. No
cell proliferation."
/evidence="ECO:0000269|PubMed:8124718"
MUTAGEN 575
/note="Y->F: Loss of CD23 gene induction; when associated
with F-603 and F-631."
/evidence="ECO:0000269|PubMed:10201973,
ECO:0000269|PubMed:8624803"
MUTAGEN 603
/note="Y->F: Loss of CD23 gene induction; when associated
with F-575 and F-631."
/evidence="ECO:0000269|PubMed:8624803"
MUTAGEN 631
/note="Y->F: Loss of CD23 gene induction; when associated
with F-575 and F-603."
/evidence="ECO:0000269|PubMed:8624803"
MUTAGEN 713
/note="Y->F: Increased IL4-induced cell proliferation and
STAT6 activation."
/evidence="ECO:0000269|PubMed:11714803"
STRAND 28..36
/evidence="ECO:0000244|PDB:1IAR"
STRAND 38..50
/evidence="ECO:0000244|PDB:1IAR"
HELIX 54..57
/evidence="ECO:0000244|PDB:1IAR"
STRAND 58..68
/evidence="ECO:0000244|PDB:1IAR"
STRAND 72..74
/evidence="ECO:0000244|PDB:1IAR"
STRAND 77..89
/evidence="ECO:0000244|PDB:1IAR"
STRAND 99..105
/evidence="ECO:0000244|PDB:1IAR"
STRAND 108..115
/evidence="ECO:0000244|PDB:1IAR"
HELIX 117..119
/evidence="ECO:0000244|PDB:1IAR"
STRAND 127..132
/evidence="ECO:0000244|PDB:1IAR"
TURN 135..137
/evidence="ECO:0000244|PDB:3BPO"
STRAND 139..144
/evidence="ECO:0000244|PDB:1IAR"
HELIX 154..156
/evidence="ECO:0000244|PDB:1IAR"
STRAND 158..168
/evidence="ECO:0000244|PDB:1IAR"
STRAND 172..177
/evidence="ECO:0000244|PDB:1IAR"
STRAND 179..181
/evidence="ECO:0000244|PDB:5E4E"
STRAND 183..186
/evidence="ECO:0000244|PDB:1IAR"
HELIX 188..190
/evidence="ECO:0000244|PDB:3BPL"
STRAND 193..195
/evidence="ECO:0000244|PDB:3BPO"
STRAND 197..204
/evidence="ECO:0000244|PDB:1IAR"
HELIX 206..208
/evidence="ECO:0000244|PDB:1IAR"
STRAND 219..221
/evidence="ECO:0000244|PDB:1IAR"
HELIX 495..497
/evidence="ECO:0000244|PDB:1IRS"
SEQUENCE 825 AA; 89658 MW; 9F886DF5612297F8 CRC64;
MGWLCSGLLF PVSCLVLLQV ASSGNMKVLQ EPTCVSDYMS ISTCEWKMNG PTNCSTELRL
LYQLVFLLSE AHTCIPENNG GAGCVCHLLM DDVVSADNYT LDLWAGQQLL WKGSFKPSEH
VKPRAPGNLT VHTNVSDTLL LTWSNPYPPD NYLYNHLTYA VNIWSENDPA DFRIYNVTYL
EPSLRIAAST LKSGISYRAR VRAWAQCYNT TWSEWSPSTK WHNSYREPFE QHLLLGVSVS
CIVILAVCLL CYVSITKIKK EWWDQIPNPA RSRLVAIIIQ DAQGSQWEKR SRGQEPAKCP
HWKNCLTKLL PCFLEHNMKR DEDPHKAAKE MPFQGSGKSA WCPVEISKTV LWPESISVVR
CVELFEAPVE CEEEEEVEEE KGSFCASPES SRDDFQEGRE GIVARLTESL FLDLLGEENG
GFCQQDMGES CLLPPSGSTS AHMPWDEFPS AGPKEAPPWG KEQPLHLEPS PPASPTQSPD
NLTCTETPLV IAGNPAYRSF SNSLSQSPCP RELGPDPLLA RHLEEVEPEM PCVPQLSEPT
TVPQPEPETW EQILRRNVLQ HGAAAAPVSA PTSGYQEFVH AVEQGGTQAS AVVGLGPPGE
AGYKAFSSLL ASSAVSPEKC GFGASSGEEG YKPFQDLIPG CPGDPAPVPV PLFTFGLDRE
PPRSPQSSHL PSSSPEHLGL EPGEKVEDMP KPPLPQEQAT DPLVDSLGSG IVYSALTCHL
CGHLKQCHGQ EDGGQTPVMA SPCCGCCCGD RSSPPTTPLR APDPSPGGVP LEASLCPASL
APSGISEKSK SSSSFHPAPG NAQSSSQTPK IVNFVSVGPT YMRVS


Related products :

Catalog number Product name Quantity
E1815h ELISA gp80,Homo sapiens,Human,IL-6 receptor subunit alpha,IL6R,IL-6R 1,IL-6R subunit alpha,IL-6RA,IL-6R-alpha,Interleukin-6 receptor subunit alpha,Membrane glycoprotein 80 96T
U1815h CLIA kit gp80,Homo sapiens,Human,IL-6 receptor subunit alpha,IL6R,IL-6R 1,IL-6R subunit alpha,IL-6RA,IL-6R-alpha,Interleukin-6 receptor subunit alpha,Membrane glycoprotein 80 96T
E1815h ELISA kit gp80,Homo sapiens,Human,IL-6 receptor subunit alpha,IL6R,IL-6R 1,IL-6R subunit alpha,IL-6RA,IL-6R-alpha,Interleukin-6 receptor subunit alpha,Membrane glycoprotein 80 96T
U1815h CLIA gp80,Homo sapiens,Human,IL-6 receptor subunit alpha,IL6R,IL-6R 1,IL-6R subunit alpha,IL-6RA,IL-6R-alpha,Interleukin-6 receptor subunit alpha,Membrane glycoprotein 80 96T
U2031h CLIA kit 582J2.1,Homo sapiens,Human,IL-4 receptor subunit alpha,IL4R,IL-4R subunit alpha,IL4RA,IL-4RA,IL-4R-alpha,Interleukin-4 receptor subunit alpha 96T
E2031h ELISA kit 582J2.1,Homo sapiens,Human,IL-4 receptor subunit alpha,IL4R,IL-4R subunit alpha,IL4RA,IL-4RA,IL-4R-alpha,Interleukin-4 receptor subunit alpha 96T
E2031h ELISA 582J2.1,Homo sapiens,Human,IL-4 receptor subunit alpha,IL4R,IL-4R subunit alpha,IL4RA,IL-4RA,IL-4R-alpha,Interleukin-4 receptor subunit alpha 96T
U2031h CLIA 582J2.1,Homo sapiens,Human,IL-4 receptor subunit alpha,IL4R,IL-4R subunit alpha,IL4RA,IL-4RA,IL-4R-alpha,Interleukin-4 receptor subunit alpha 96T
E0229h ELISA kit Homo sapiens,Human,IL-2 receptor subunit alpha,IL-2R subunit alpha,IL2RA,IL-2-RA,IL2-RA,Interleukin-2 receptor subunit alpha,p55,TAC antigen 96T
E0229h ELISA Homo sapiens,Human,IL-2 receptor subunit alpha,IL-2R subunit alpha,IL2RA,IL-2-RA,IL2-RA,Interleukin-2 receptor subunit alpha,p55,TAC antigen 96T
U0229h CLIA Homo sapiens,Human,IL-2 receptor subunit alpha,IL-2R subunit alpha,IL2RA,IL-2-RA,IL2-RA,Interleukin-2 receptor subunit alpha,p55,TAC antigen 96T
E1815m ELISA kit IL-6 receptor subunit alpha,Il6r,IL-6R 1,IL-6R subunit alpha,Il6ra,IL-6RA,IL-6R-alpha,Interleukin-6 receptor subunit alpha,Mouse,Mus musculus 96T
U2031m CLIA kit IL-4 receptor subunit alpha,Il4r,IL-4R subunit alpha,Il4ra,IL-4RA,IL-4R-alpha,Interleukin-4 receptor subunit alpha,Mouse,Mus musculus 96T
E1815r ELISA kit IL-6 receptor subunit alpha,Il6r,IL-6R 1,IL-6R subunit alpha,Il6ra,IL-6RA,IL-6R-alpha,Interleukin-6 receptor subunit alpha,Rat,Rattus norvegicus 96T
U1815r CLIA IL-6 receptor subunit alpha,Il6r,IL-6R 1,IL-6R subunit alpha,Il6ra,IL-6RA,IL-6R-alpha,Interleukin-6 receptor subunit alpha,Rat,Rattus norvegicus 96T
E2031r ELISA kit IL-4 receptor subunit alpha,Il4r,IL-4R subunit alpha,Il4ra,IL-4RA,IL-4R-alpha,Interleukin-4 receptor subunit alpha,Rat,Rattus norvegicus 96T
E1815r ELISA IL-6 receptor subunit alpha,Il6r,IL-6R 1,IL-6R subunit alpha,Il6ra,IL-6RA,IL-6R-alpha,Interleukin-6 receptor subunit alpha,Rat,Rattus norvegicus 96T
U1815m CLIA IL-6 receptor subunit alpha,Il6r,IL-6R 1,IL-6R subunit alpha,Il6ra,IL-6RA,IL-6R-alpha,Interleukin-6 receptor subunit alpha,Mouse,Mus musculus 96T
U1815m CLIA kit IL-6 receptor subunit alpha,Il6r,IL-6R 1,IL-6R subunit alpha,Il6ra,IL-6RA,IL-6R-alpha,Interleukin-6 receptor subunit alpha,Mouse,Mus musculus 96T
U1815r CLIA kit IL-6 receptor subunit alpha,Il6r,IL-6R 1,IL-6R subunit alpha,Il6ra,IL-6RA,IL-6R-alpha,Interleukin-6 receptor subunit alpha,Rat,Rattus norvegicus 96T
E2031m ELISA IL-4 receptor subunit alpha,Il4r,IL-4R subunit alpha,Il4ra,IL-4RA,IL-4R-alpha,Interleukin-4 receptor subunit alpha,Mouse,Mus musculus 96T
U2031m CLIA IL-4 receptor subunit alpha,Il4r,IL-4R subunit alpha,Il4ra,IL-4RA,IL-4R-alpha,Interleukin-4 receptor subunit alpha,Mouse,Mus musculus 96T
U2031r CLIA IL-4 receptor subunit alpha,Il4r,IL-4R subunit alpha,Il4ra,IL-4RA,IL-4R-alpha,Interleukin-4 receptor subunit alpha,Rat,Rattus norvegicus 96T
U2031r CLIA kit IL-4 receptor subunit alpha,Il4r,IL-4R subunit alpha,Il4ra,IL-4RA,IL-4R-alpha,Interleukin-4 receptor subunit alpha,Rat,Rattus norvegicus 96T
E2031r ELISA IL-4 receptor subunit alpha,Il4r,IL-4R subunit alpha,Il4ra,IL-4RA,IL-4R-alpha,Interleukin-4 receptor subunit alpha,Rat,Rattus norvegicus 96T
Pathways :
WP1566: Citrate cycle (TCA cycle)
WP1655: Geraniol degradation
WP1614: 1- and 2-Methylnaphthalene degradation
WP1963: The effect of Glucocorticoids on target gene expression
WP2292: Chemokine signaling pathway
WP566: canonical wnt - zebrafish
WP2272: Pathogenic Escherichia coli infection
WP1531: Vitamin D synthesis
WP210: Cytoplasmic Ribosomal Proteins
WP2199: Seed Development
WP2100: AhR pathway
WP1003: Ovarian Infertility Genes
WP537: Translation Factors
WP2359: Parkin-Ubiquitin Proteasomal System pathway
WP1571: EBV LMP1 signaling
WP34: Ovarian Infertility Genes
WP246: TNF-alpha NF-kB Signaling Pathway
WP1209: EBV LMP1 signaling
WP1835: Interferon alpha/beta signaling
WP457: TNF-alpha NF-kB Signaling Pathway
WP273: Ovarian Infertility Genes
WP296: TCA Cycle - biocyc
WP1340: Ovarian Infertility Genes
WP1163: TNF-alpha NF-kB Signaling Pathway
WP32: Translation Factors

Related Genes :
[IL4R IL4RA 582J2.1] Interleukin-4 receptor subunit alpha (IL-4 receptor subunit alpha) (IL-4R subunit alpha) (IL-4R-alpha) (IL-4RA) (CD antigen CD124) [Cleaved into: Soluble interleukin-4 receptor subunit alpha (Soluble IL-4 receptor subunit alpha) (Soluble IL-4R-alpha) (sIL4Ralpha/prot) (IL-4-binding protein) (IL4-BP)]
[Il4r Il4ra] Interleukin-4 receptor subunit alpha (IL-4 receptor subunit alpha) (IL-4R subunit alpha) (IL-4R-alpha) (IL-4RA) (CD antigen CD124) [Cleaved into: Soluble interleukin-4 receptor subunit alpha (Soluble IL-4 receptor subunit alpha) (Soluble IL-4R-alpha) (sIL4Ralpha/prot) (IL-4-binding protein) (IL4-BP)]
[Il4r Il4ra] Interleukin-4 receptor subunit alpha (IL-4 receptor subunit alpha) (IL-4R subunit alpha) (IL-4R-alpha) (IL-4RA) (CD antigen CD124)
[IL4R] Interleukin-4 receptor subunit alpha (IL-4 receptor subunit alpha) (IL-4R subunit alpha) (IL-4R-alpha) (IL-4RA) (CD antigen CD124)
[IL13RA1 IL13R IL13RA] Interleukin-13 receptor subunit alpha-1 (IL-13 receptor subunit alpha-1) (IL-13R subunit alpha-1) (IL-13R-alpha-1) (IL-13RA1) (Cancer/testis antigen 19) (CT19) (CD antigen CD213a1)
[IL6R] Interleukin-6 receptor subunit alpha (IL-6 receptor subunit alpha) (IL-6R subunit alpha) (IL-6R-alpha) (IL-6RA) (IL-6R 1) (Membrane glycoprotein 80) (gp80) (CD antigen CD126) [Cleaved into: Soluble interleukin-6 receptor subunit alpha (sIL6R)]
[IL15RA] Interleukin-15 receptor subunit alpha (IL-15 receptor subunit alpha) (IL-15R-alpha) (IL-15RA) (CD antigen CD215) [Cleaved into: Soluble interleukin-15 receptor subunit alpha (sIL-15 receptor subunit alpha) (sIL-15R-alpha) (sIL-15RA)]
[IL11RA] Interleukin-11 receptor subunit alpha (IL-11 receptor subunit alpha) (IL-11R subunit alpha) (IL-11R-alpha) (IL-11RA) [Cleaved into: Soluble interleukin-11 receptor subunit alpha (sIL-11R) (sIL-11RA) (sIL11RA)]
[Il11ra1 Etl2 Il11ra] Interleukin-11 receptor subunit alpha-1 (IL-11 receptor subunit alpha-1) (IL-11R subunit alpha-1) (IL-11R-alpha-1) (IL-11RA1) (Enhancer trap locus homolog 2) (Etl-2) (Novel cytokine receptor 1) (NR-1) (NR1) [Cleaved into: Soluble interleukin-11 receptor subunit alpha (sIL-11R) (sIL-11RA) (sIL11RA)]
[IL1R1 IL1R IL1RA IL1RT1] Interleukin-1 receptor type 1 (IL-1R-1) (IL-1RT-1) (IL-1RT1) (EC 3.2.2.6) (CD121 antigen-like family member A) (Interleukin-1 receptor alpha) (IL-1R-alpha) (Interleukin-1 receptor type I) (p80) (CD antigen CD121a) [Cleaved into: Interleukin-1 receptor type 1, membrane form (mIL-1R1) (mIL-1RI); Interleukin-1 receptor type 1, soluble form (sIL-1R1) (sIL-1RI)]
[IL4R] Interleukin-4 receptor subunit alpha (IL-4 receptor subunit alpha) (IL-4R subunit alpha) (IL-4R-alpha) (IL-4RA) (CD antigen CD124)
[Il1r1 Il-1r1 Il1ra] Interleukin-1 receptor type 1 (IL-1R-1) (IL-1RT-1) (IL-1RT1) (EC 3.2.2.6) (CD121 antigen-like family member A) (Interleukin-1 receptor alpha) (IL-1R-alpha) (Interleukin-1 receptor type I) (p80) (CD antigen CD121a) [Cleaved into: Interleukin-1 receptor type 1, membrane form (mIL-1R1) (mIL-1RI); Interleukin-1 receptor type 1, soluble form (sIL-1R1) (sIL-1RI)]
[Il1r1 Il1ra] Interleukin-1 receptor type 1 (IL-1R-1) (IL-1RT-1) (IL-1RT1) (EC 3.2.2.6) (CD121 antigen-like family member A) (Interleukin-1 receptor alpha) (IL-1R-alpha) (Interleukin-1 receptor type I) (p80) (CD antigen CD121a) [Cleaved into: Interleukin-1 receptor type 1, membrane form (mIL-1R1) (mIL-1RI); Interleukin-1 receptor type 1, soluble form (sIL-1R1) (sIL-1RI)]
[IL13RA2 IL13R] Interleukin-13 receptor subunit alpha-2 (IL-13 receptor subunit alpha-2) (IL-13R subunit alpha-2) (IL-13R-alpha-2) (IL-13RA2) (Interleukin-13-binding protein) (CD antigen CD213a2)
[IL10RA IL10R] Interleukin-10 receptor subunit alpha (IL-10 receptor subunit alpha) (IL-10R subunit alpha) (IL-10RA) (CDw210a) (Interleukin-10 receptor subunit 1) (IL-10R subunit 1) (IL-10R1) (CD antigen CD210)
[IL7R] Interleukin-7 receptor subunit alpha (IL-7 receptor subunit alpha) (IL-7R subunit alpha) (IL-7R-alpha) (IL-7RA) (CDw127) (CD antigen CD127)
[IL18R1 IL1RRP] Interleukin-18 receptor 1 (IL-18R-1) (IL-18R1) (EC 3.2.2.6) (CD218 antigen-like family member A) (CDw218a) (IL1 receptor-related protein) (IL-1Rrp) (IL1R-rp) (Interleukin-18 receptor alpha) (IL-18R-alpha) (IL-18Ralpha) (CD antigen CD218a)
[IL5RA IL5R] Interleukin-5 receptor subunit alpha (IL-5 receptor subunit alpha) (IL-5R subunit alpha) (IL-5R-alpha) (IL-5RA) (CDw125) (CD antigen CD125)
[IL6ST] Interleukin-6 receptor subunit beta (IL-6 receptor subunit beta) (IL-6R subunit beta) (IL-6R-beta) (IL-6RB) (CDw130) (Interleukin-6 signal transducer) (Membrane glycoprotein 130) (gp130) (Oncostatin-M receptor subunit alpha) (CD antigen CD130)
[Il7r] Interleukin-7 receptor subunit alpha (IL-7 receptor subunit alpha) (IL-7R subunit alpha) (IL-7R-alpha) (IL-7RA) (CD antigen CD127)
[IL31RA CRL3 GPL UNQ6368/PRO21073/PRO21384] Interleukin-31 receptor subunit alpha (IL-31 receptor subunit alpha) (IL-31R subunit alpha) (IL-31R-alpha) (IL-31RA) (Cytokine receptor-like 3) (GLM-R) (hGLM-R) (Gp130-like monocyte receptor) (Gp130-like receptor) (ZcytoR17)
[Il3ra Sut-1] Interleukin-3 receptor subunit alpha (IL-3 receptor subunit alpha) (IL-3R subunit alpha) (IL-3R-alpha) (IL-3RA) (Interleukin-3 receptor class II alpha chain) (CD antigen CD123)
[IL3RA IL3R] Interleukin-3 receptor subunit alpha (IL-3 receptor subunit alpha) (IL-3R subunit alpha) (IL-3R-alpha) (IL-3RA) (CD antigen CD123)
[IFNLR1 IL28RA LICR2] Interferon lambda receptor 1 (IFN-lambda receptor 1) (IFN-lambda-R1) (Cytokine receptor class-II member 12) (Cytokine receptor family 2 member 12) (CRF2-12) (Interleukin-28 receptor subunit alpha) (IL-28 receptor subunit alpha) (IL-28R-alpha) (IL-28RA) (Likely interleukin or cytokine receptor 2) (LICR2)
[IL2RG] Cytokine receptor common subunit gamma (Interleukin-2 receptor subunit gamma) (IL-2 receptor subunit gamma) (IL-2R subunit gamma) (IL-2RG) (gammaC) (p64) (CD antigen CD132)
[Il6st] Interleukin-6 receptor subunit beta (IL-6 receptor subunit beta) (IL-6R subunit beta) (IL-6R-beta) (IL-6RB) (Interleukin-6 signal transducer) (Membrane glycoprotein 130) (gp130) (Oncostatin-M receptor subunit alpha) (CD antigen CD130)
[Il6st] Interleukin-6 receptor subunit beta (IL-6 receptor subunit beta) (IL-6R subunit beta) (IL-6R-beta) (IL-6RB) (Interleukin-6 signal transducer) (Membrane glycoprotein 130) (gp130) (Oncostatin-M receptor subunit alpha) (CD antigen CD130)
[IL27RA CRL1 TCCR WSX1 UNQ296/PRO336] Interleukin-27 receptor subunit alpha (IL-27 receptor subunit alpha) (IL-27R subunit alpha) (IL-27R-alpha) (IL-27RA) (Cytokine receptor WSX-1) (Cytokine receptor-like 1) (Type I T-cell cytokine receptor) (TCCR) (ZcytoR1)
[Il11ra1] Interleukin-11 receptor subunit alpha (IL-11 receptor subunit alpha) (IL-11R subunit alpha) (IL-11R-alpha) (IL-11RA) [Cleaved into: Soluble interleukin-11 receptor subunit alpha (sIL-11R) (sIL-11RA) (sIL11RA)]
[Il27ra Tccr Wsx1] Interleukin-27 receptor subunit alpha (IL-27 receptor subunit alpha) (IL-27R subunit alpha) (IL-27R-alpha) (IL-27RA) (Type I T-cell cytokine receptor) (TCCR) (WSX-1)

Bibliography :
No related Items